Download MendeleyNonpeptidic inhibitors of human leukocyte elastase. 6. Design of a potent, intratracheally active, pyridone-based trifluoromethyl ketone.
Bernstein, P.R., Gomes, B.C., Kosmider, B.J., Vacek, E.P., Williams, J.C.(1995) J Med Chem 38: 212-215
- PubMed: 7837235 Search on PubMed
- DOI: 10.1021/jm00001a028
- Primary Citation of Related Structures:
1EAU - PubMed Abstract:
- Nonpeptidic Inhibitors of Human Leukocyte Elastase. 5. Design, Synthesis, and X-Ray Crystallography of a Series of Orally Active 5-Amino-Pyrimidin-6-One-Containing Trifluoromethylketones
Veale, C.A., Bernstein, P.R., Bryant, C., Ceccarelli, C., Damewood, J.R., Earley, R., Feeney, S.W., Gomes, B., Kosmider, B.J., Steelman, G.B., Thomas, R.M., Vacek, E.P., Williams, J.C., Wolanin, D.J., Woolson, S.
() To be published --: -- - Nonpeptidic Inhibitors of Human Leukocyte Elastase. 4. Design, Synthesis,in Vitro, and in Vivo Activity of a Series of Beta-Carbolinone-Containing Trifluoromethyl Ketones
Veale, C.A., Damewood, J.R., Steelman, G.B., Bryant, C., Gomes, B., Williams, J.
() To be published --: -- - Nonpeptidic Inhibitors of Human Leukocyte Elastase. 3. Design, Synthesis, X-Ray Crystallographic Analysis, and Structure-Activity Relationships for a Series of Orally Active 3-Amino-6-Phenylpyridin-2-One Trifluoromethyl Ketones
Bernstein, P.R., Andisik, D., Bradley, P.K., Bryant, C.B., Ceccarelli, C., Damewood, J.R., Earley, R., Edwards, P.D., Feeney, S., Gomes, B.C., Kosmider, B.J., Steelman, G.B., Thomas, R.M., Vacek, E.P., Veale, C.A., Williams, J.C., Wolanin, D.J., Woolson, S.A.
(1994) J Med Chem 37: 3313 - Nonpeptidic Inhibitors of Human Leukocyte Elastase. 2. Design, Synthesis and in Vitro Activity of a Series of 3-Amino-6-Arylpyridin-2-One Trifluoromethyl Ketones
Damewood, J.R., Edwards, P.D., Feeney, S., Gomes, B.C., Steelman, G.B., Tuthill, P.A., Warner, P., Williams, J.C., Woolson, S.A., Wolanin, D., Veale, C.
(1994) J Med Chem 37: 3303 - Nonpeptidic Inhibitors of Human Leukocyte Elastase. 1. The Design and Synthesis of Pyridone-Containing Inhibitors
Warner, P., Green, R.C., Gomes, B.C., Williams, J.C.
(1994) J Med Chem 37: 3090 - Design of Orally Active, Nonpeptidic Inhibitors of Human Leukocyte Elastase
Brown, F.J., Andisik, D.W., Bernstein, P.R., Bryant, C.B., Ceccarelli, C., Damewood, J.R., Edwards, P.D., Earley, R., Feeney, S.W., Green, R.C., Gomes, B., Kosmider, B.J., Krell, R., Shaw, A., Steelman, G.B., Thomas, R.M., Vacek, E.P., Veale, C.A., Tuthill, P.A., Warner, P., Williams, J.C., Wolanin, D.J., Woolson, S.A.
(1994) J Med Chem 37: 1259 - Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl Alpha-Ketobenzoxazoles,and the X-Ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole
Edwards, P.D., Meyer, E.F., Vijayalakshmi, J., Tuthill, P.A., Andisik, D.A., Gomes, B., Strimpler, A.
(1992) J Am Chem Soc 114: 1854 - Crystal Structure of the Covalent Complex Formed by a Peptidyl Alpha,Alpha-Difluoro-Beta-Keto Amide with Porcine Pancreatic Elastase at 1.78-Angstrom Resolution
Takahashi, L.H., Radhakrishnan, R., Rosenfield, R.E., Meyer, E.F., Trainor, D.A.
(1989) J Am Chem Soc 111: 3368 - X-Ray Diffraction Analysis of the Inhibition of Porcine Pancreatic Elastase by a Peptidyl Trifluoromethylketone
Takahashi, L.H., Radhakrishnan, R., Rosenfield, R.E., Meyer, E.F., Trainor, D.A., Stein, M.
(1988) J Mol Biol 201: 423
Further modification of the 3-amino substituent in a trifluoromethyl ketone-based series of 3-amino-6-phenylpyridin-2-ones that had been optimized for oral activity led to analogs that were potent intratracheal inhibitors in a model of HLE-induced lung damage in the hamster ...
Further modification of the 3-amino substituent in a trifluoromethyl ketone-based series of 3-amino-6-phenylpyridin-2-ones that had been optimized for oral activity led to analogs that were potent intratracheal inhibitors in a model of HLE-induced lung damage in the hamster. The best 3-amino substituent for intratracheal activity is [4-[N-[(4-chlorophenyl)sulfonyl]-carbamoyl]phenyl]sulfonyl. At a 30 min prechallenge interval, compound 9, which incorporates this substituent, had an ED50 of approximately 2 nmol/animal and, qualitatively, afforded a very similar dose-response relationship to that found with a peptidic trifluoromethyl ketone inhibitor, ICI 200,355.
Related Citations:
Organizational Affiliation:
Department of Medicinal Chemistry, ZENECA Pharmaceuticals, Wilmington, Delaware 19897.
